FHIR © HL7.org  |  Server Home  |  FHIR Server FHIR Server 3.7.21  |  FHIR Version n/a  User: [n/a]

773879000: Antineoplastic therapeutic role (role)

Status: current, Not sufficiently defined by necessary conditions definition status. Date: 31-Jan 2019. Module: SNOMED CT core module

Descriptions:

Id Description Lang Type Status Case? Module
3726859011 Antineoplastic therapeutic role en Synonym Active Entire term case insensitive SNOMED CT core module
3726860018 Antineoplastic therapeutic role (role) en Fully specified name Active Entire term case insensitive SNOMED CT core module

0 descendants.

Expanded Value Set

Outbound Relationships Type Target Active Characteristic Refinability Group Values
Antineoplastic therapeutic role Is a Therapeutic role true Inferred relationship Existential restriction modifier
Inbound Relationships Type Active Source Characteristic Refinability Group
Product containing precisely etoposide 50 milligram/1 each conventional release oral capsule Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely etoposide 100 milligram/1 each conventional release oral capsule Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing ruxolitinib Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Ruxolitinib Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing only ruxolitinib in oral dose form (medicinal product form) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely ruxolitinib (as ruxolitinib phosphate) 10 milligram/1 each conventional release oral tablet (clinical drug) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely ruxolitinib (as ruxolitinib phosphate) 5 milligram/1 each conventional release oral tablet (clinical drug) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely ruxolitinib 20 milligram/1 each conventional release oral tablet Plays role False Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely ruxolitinib 15 milligram/1 each conventional release oral tablet Plays role False Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely ruxolitinib 25 milligram/1 each conventional release oral tablet Plays role False Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing ruxolitinib in oral dose form (medicinal product form) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing only romidepsin (medicinal product) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely romidepsin 10 milligram/1 vial powder for conventional release solution for injection (clinical drug) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing romidepsin in parenteral dose form (medicinal product form) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing only romidepsin in parenteral dose form (medicinal product form) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing romidepsin Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing sorafenib Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Sorafenib Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing only sorafenib in oral dose form (medicinal product form) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely sorafenib (as sorafenib tosylate) 200 milligram/1 each conventional release oral tablet Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing sorafenib in oral dose form (medicinal product form) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing regorafenib Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Regorafenib Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing only regorafenib in oral dose form (medicinal product form) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely regorafenib 40 milligram/1 each conventional release oral tablet Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing regorafenib in oral dose form (medicinal product form) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Raltitrexed Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing only raltitrexed in parenteral dose form (medicinal product form) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing raltitrexed Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely raltitrexed 2 milligram/1 vial powder for conventional release solution for injection Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing raltitrexed in parenteral dose form (medicinal product form) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Streptozocin Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing streptozocin in parenteral dose form (medicinal product form) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing only streptozocin in parenteral dose form (medicinal product form) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely streptozocin 1 gram/1 vial powder for conventional release solution for injection (clinical drug) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing streptozocin Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing sunitinib Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Sunitinib Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing only sunitinib in oral dose form (medicinal product form) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely sunitinib (as sunitinib malate) 25 milligram/1 each conventional release oral capsule Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely sunitinib (as sunitinib malate) 12.5 milligram/1 each conventional release oral capsule Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely sunitinib (as sunitinib malate) 50 milligram/1 each conventional release oral capsule Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing sunitinib in oral dose form (medicinal product form) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Panobinostat Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing panobinostat Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Panitumumab Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing only panitumumab in parenteral dose form (medicinal product form) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely panitumumab 20 milligram/1 milliliter conventional release solution for injection (clinical drug) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing panitumumab Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing panitumumab in parenteral dose form (medicinal product form) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing pentostatin Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Pentostatin Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing only pentostatin in parenteral dose form (medicinal product form) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely pentostatin 10 milligram/1 vial powder for conventional release solution for injection Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing pentostatin in parenteral dose form (medicinal product form) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Pegaspargase Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing only pegaspargase in parenteral dose form (medicinal product form) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely pegaspargase 750 unit/1 milliliter conventional release solution for injection (clinical drug) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing pegaspargase Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing pegaspargase in parenteral dose form (medicinal product form) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Pemetrexed Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing pemetrexed in parenteral dose form (medicinal product form) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing only pemetrexed in parenteral dose form (medicinal product form) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely pemetrexed (as pemetrexed disodium) 500 milligram/1 vial powder for conventional release solution for injection (clinical drug) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely pemetrexed (as pemetrexed disodium) 100 milligram/1 vial powder for conventional release solution for injection (clinical drug) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing pemetrexed Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing only vandetanib in oral dose form (medicinal product form) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing vandetanib in oral dose form (medicinal product form) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely vandetanib 100 milligram/1 each conventional release oral tablet (clinical drug) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely vandetanib 300 milligram/1 each conventional release oral tablet (clinical drug) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing vandetanib Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Vandetanib Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing only valrubicin in intravesical dose form (medicinal product form) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing valrubicin in intravesical dose form (medicinal product form) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing valrubicin Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing only valrubicin (medicinal product) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely neratinib (as neratinib maleate) 40 milligram/1 each conventional release oral tablet (clinical drug) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing only neratinib in oral dose form (medicinal product form) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Neratinib Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing neratinib Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing neratinib in oral dose form (medicinal product form) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing only nelarabine in parenteral dose form (medicinal product form) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing nelarabine in parenteral dose form (medicinal product form) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Nelarabine Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing nelarabine Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing brentuximab vedotin in parenteral dose form (medicinal product form) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing only brentuximab vedotin in parenteral dose form (medicinal product form) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing brentuximab vedotin Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Brentuximab vedotin Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely necitumumab 16 milligram/1 milliliter conventional release solution for injection (clinical drug) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing necitumumab (medicinal product) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Necitumumab Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely fedratinib (as fedratinib hydrochloride) 100 milligram/1 each conventional release oral capsule (clinical drug) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Blinatumomab Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing only blinatumomab in parenteral dose form (medicinal product form) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing blinatumomab Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing blinatumomab in parenteral dose form (medicinal product form) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing bortezomib in parenteral dose form (medicinal product form) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing only bortezomib in parenteral dose form (medicinal product form) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing bortezomib Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Bortezomib Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier

Start Previous Page 5 of 26 Next End

This concept is not in any reference sets

Back to Start